Kymera Therapeutics, Inc. (NASDAQ:KYMR)
| Market Cap | 8.68B+87.5% |
| Revenue (ttm) | 104.99M+134.8% |
| Net Income | -299.65M-8.8% |
| EPS | -3.25+6.3% |
| Shares Out | 82.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 184,542.682 |
| Open | 106.52 |
| Previous Close | 108.35 |
| Day's Range | 104.19 - 107.85 |
| 52-Week Range | 55.26 - 130.05 |
| Beta | 1.98 |
| Analysts | Buy |
| Price Target | 138.07(+30.82%) |
| Earnings Date | Nov 3, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About KYMR
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$KYMR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in KYMR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KYMR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KYMR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New KYMR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KYMR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KYMR
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $248.79M |
| VBVanguard Morningstar Small-Cap ETF | $179.93M |
| IWMiShares Russell 2000 ETF | $178.21M |
| XBIState Street SPDR S&P Biotech ETF | $118.78M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $103.26M |
| VXFVanguard Extended Market ETF | $87.46M |
Estimated from each fund’s disclosed top holdings × AUM
KYMR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from KYMR’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score